FDA Grants Fast Track Designation to SOT106 for Soft Tissue Sarcoma Treatment
“Soft tissue sarcomas (STS) remain a major unmet medical need, where decades of therapeutic progress have yet to translate into meaningful improvements for patients with advanced or recurrent disease,” said Vivi Boura, M.D., chief medical officer of SOTIO. “Receiving Fast Track Designation for SOT106 is an important regulatory milestone that reinforces this program’s potential to improve outcomes for patients facing these difficult-to-treat cancers. As we advance SOT106 toward the clinic, we aim to translate its differentiated design and LRRC15-targeting strategy into a novel therapeutic approach with the potential to offer a new treatment option for patients across multiple soft tissue sarcoma subtypes.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib